Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Evotec gets $50 million US contract for plague antibodies

by Gina Vitale
September 25, 2022 | A version of this story appeared in Volume 100, Issue 34

 

A biologic-drug manufacturing facility.
Credit: Evotec
Evotec's facility in Redmond, Washington, will produces biologics for the US Department of Defense.

The US Department of Defense has awarded Evotec a contract of up to $49.9 million to quickly develop monoclonal antibodies against plague. Plague is a bacterial disease that still infects people in parts of Africa, Asia, and the western US, according to the US Centers for Disease Control and Prevention. The firm’s drug services Just–Evotec Biologics unit will be responsible for development through Phase 1 first-in-human trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.